Celsion Corporation (CLSN) saw its loss narrow to $22.05 million, or $0.85 a share for the year ended Dec. 31, 2016. In the previous year period, the company reported a loss of $22.46 million, or $1.03 a share. Revenue during the year was stable at $0.50 million, when compared with the last year.
Operating loss for the year was $20.65 million, compared with an operating loss of $20.85 million in the previous year.
"Celsion had an exceedingly productive 2016 as our accomplishments, one after another, established meaningful progress with respect to our two leading-edge technology platforms designed to enhance clinically powerful therapies. With sound fundamentals, the superb execution of our ongoing global, pivotal Phase III OPTIMA Study in primary liver cancer, continues to attract interest and support from the medical community, international regulatory agencies, and research organizations like the National Institutes of Health for this ground-breaking study," said Michael H. Tardugno, Celsion's chairman, president and CEO.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
